Dr Franz H. Messerli discusses treatment of hypertension in the elderly patients, the idea of setting universal blood pressure targets, and the results of SPRINT in a conversation with Dr Jerzy Gąsowski.
In 2017 ESC guidelines on STEMI management, the presence of RBBB, similarly to LBBB, is now an indication for urgent coronary angiography in patients with symptoms of myocardial ischemia. What is this based on? Should every patient with features of MI and RBBB in ECG undergo urgent coronary angiography? Does it apply only to patients with a new block or also to those with a preexisting block?
What is the optimal treatment of heart failure in patients with preserved, reduced, or mid-range LVEF? Should patients with mid-range LVEF be treated similarly to those with reduced LVEF?
What are the current guidelines for monitoring adverse effects in patients treated with statins?
What are the most common errors in the treatment of dyslipidemia?
In what patients should we suspect familial dyslipidemia?
Which patients with hypercholesterolemia may be offered new lipid-lowering drugs, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors?
What are the absolute contraindications to the administration of acetylsalicylic acid in patients with suspected acute coronary syndrome during prehospital care?
Are there any differences in the treatment of patients with myocardial infarction after noncardiac surgery compared to other patients with myocardial infraction? How is the management influenced by a history of coronary artery disease and previous percutaneous coronary intervention?
What is the threshold for low-density lipoprotein cholesterol levels for starting statins in otherwise healthy middle-aged men or women?
